Arctigenin Promotes Apoptosis in Ovarian Cancer Cells via the iNOS/NO/STAT3/Survivin Signalling

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 6, 2014, Pages 507-511

  Huang, Ke ^a   Li, Li An ^a   Meng, Yuan Guang ^a   You, Yan Qin ^a   Fu, Xiao Yu ^a   Song, Lei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARCTIGENIN; CASPASE 3; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; STAT3 PROTEIN; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; FURAN DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; LIGNAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE; WESTERN BLOTTING;

ARCTIUM LAPPA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; FEMALE; FURANS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIGNANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84925937934     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12270     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009;112:275-81.
3. Mir R, Stanzani E, Martinez-Soler F, Villanueva A, Vidal A, Condom E et al. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression. Gynecol Oncol 2014;132:211-20.
4. Nguyen AV, Wu YY, Liu Q, Wang D, Nguyen S, Loh R et al. STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. Neoplasia 2013;15:998-1008.
5. Aittomäki S, Pesu M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin Pharmacol Toxicol 2014;114:18-23.
6. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9.
7. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006;12:5055-63.
8. Han Z, Feng J, Hong Z, Chen L, Li W, Liao S et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun 2013;435:188-94.
9. Jiang Q, Dai L, Cheng L, Chen X, Li Y, Zhang S et al. Efficient inhibition of intraperitoneal ovarian cancer growth in nude mice by liposomal delivery of short hairpin RNA against STAT3. J Obstet Gynaecol Res 2013;39:701-9.
10. Zhao F, Wang L, Liu K. In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J Ethnopharmacol 2009;122:457-62.
11. Wang HQ, Jin JJ, Wang J. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression. J Biochem Mol Toxicol 2014;28:39-45.
12. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 2008;19:133-7.
13. Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A et al. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 2008;68:5159-66.
14. Yao X, Zhu F, Zhao Z, Liu C, Luo L, Yin Z. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. J Cell Biochem 2011;112:2837-49.
15. Kim JY, Hwang JH, Cha MR, Yoon MY, Son ES, Tomida A et al. Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity. J Cell Physiol 2010;224:33-40.
16. Jeong JB, Hong SC, Jeong HJ, Koo JS. Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells. Int Immunopharmacol 2011;11:1573-7.
17. Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM, Hsu YL. Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic Biol Med 2014;67:159-70.
18. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012;109:9623-8.
19. Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther 2012;13:766-75.
20. Wenzel U, Kuntz S, De Sousa UJ, Daniel H. Nitric oxide suppresses apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Int J Cancer 2003;106:666-75.
21. Thomas LN, Morehouse TJ, Too CK. Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Prostate 2012;72:450-60.
22. Kou X, Qi S, Dai W, Luo L, Yin Z. Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264.7 cells through suppressing JAK-STAT signal pathway. Int Immunopharmacol 2011;11:1095-102.
23. Yao X, Li G, Lü C, Xu H, Yin Z. Arctigenin promotes degradation of inducible nitric oxide synthase through CHIP-associated proteasome pathway and suppresses its enzyme activity. Int Immunopharmacol 2012;14:138-44.
24. Kim J, Won JS, Singh AK, Sharma AK, Singh I. STAT3 Regulation by S-Nitrosylation: implication for Inflammatory Disease. Antioxid Redox Signal 2014;20:2514-27.